X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TRC101 (veverimer), a non-absorbed, orally administered polymer has ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
TRC101 (veverimer), is novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in GIT and removing it from body through excretion in feces, thereby decreasing total amount of acid in body and increasing serum bicarbonate.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
TRC101 (veverimer), a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract is specifically designed to combine high capacity and high selectivity for binding and removing hydrochloric acid.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Veverimer, also known as TRC101, is a novel, non-absorbed polymer that is designed to treat metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
Tricida investigational drug candidate, Veverimer, an orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD, is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
The net proceeds will be used to fund corporate operations, including the VALOR-CKD renal outcomes trial evaluating Veverimer, and are expected to extend Tricida’s financial runway into the first quarter of 2023.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $42.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 15, 2021
Details:
The patent expands the composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio to a total of 210 patents in 49 different countries. Veverimer is a non-absorbed, orally-administered polymer for metabolic acidosis in patients with CKD.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
Tricida Has Received an Appeal Denied Letter from the Office of New Drugs of the FDA in Response to its Formal Dispute Resolution Request. The ongoing VALOR-CKD trial is a renal outcomes clinical trial designed to determine if veverimer slows CKD progression.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2021
Details:
Tricida has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for veverimer on August 21, 2020. The NDA was reviewed under the Accelerated Approval Program.
Lead Product(s): Veverimer
Therapeutic Area: Nephrology Product Name: TRC101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
